Glutamate administration is associated with aggravated atherosclerosis and altered expression of RAPGEF1, OPN, and MYL7 in High-Fat Diet-Fed ApoE⁻/⁻ Mice
PLOS One · 28.07.2026 · 21 (7) · e0354719
DOI: 10.1371/journal.pone.0354719 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 28.07.2026. Verfasst von Xiuli Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Huanhu Hospital Affiliated to Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Diet, High-Fat, Atherosclerosis, Apolipoproteins E, Glutamic Acid. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Project of Tianjin Municipal Education Commission, Tianjin Key Medical Discipline Construction Project.
Abstract (Originalsprache)
Objective
This study aims to examine whether oral glutamate administration is associated with accelerated atherosclerosis progression in high-fat diet-fed ApoE ⁻ / ⁻ mice and to identify candidate protein associated with this process.
Methods
Atherosclerosis (AS) was induced in ApoE ⁻ / ⁻ mice by feeding a high-fat diet (HFD) for three months. The mice were randomly divided into four groups: (1) the AS-GLU group, receiving glutamate with HFD; (2) the AS group, receiving HFD with placebo; (3) the Glu group, receiving glutamate with normal chow; and (4) the Control group, receiving normal chow with a placebo. Atherosclerotic lesions were assessed using Lillie's oil red O staining and histological analysis. LC-MS/MS based proteomics profiling was employed to identify differentially expressed proteins, with subsequent validation by Western blotting and qPCR.
Results
Glutamate administration alone (Glu group) induced minimal plaque formation. The combination of HFD and glutamate (AS-GLU) was associated with a greater atherosclerotic plaque area compared to HFD alone (AS group). Proteomics identified RAPGEF1, OPN, and MYL7 as proteins whose expression was increased in the AS-GLU group compared to AS group. These associations were confirmed by Western blot and qPCR.
Conclusions
This study shows that oral glutamate administration, in the context of a high-fat diet in ApoE ⁻ / ⁻ mice, is associated with exacerbated atherosclerosis and increased expression of RAPGEF1, OPN, and MYL7. These proteins represent candidate molecules associated with glutamate exposure, but their causal role remains to be determined. Serum glutamate levels were not significantly elevated, and lipid profile changes may also contribute to the observed associations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Huanhu Hospital Affiliated to Tianjin Medical University, Tianjin, China.
- Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin, China.
ORCID-Profile: Fanshu Dai, Biao Zhang
Förderung
- Scientific Research Project of Tianjin Municipal Education Commission
- Tianjin Key Medical Discipline Construction Project
Zitieren
APA
Cheng, X., Dai, F., Mahmut, D., Huang, X., Wang, Q., & Zhang, B. (2026). Glutamate administration is associated with aggravated atherosclerosis and altered expression of RAPGEF1, OPN, and MYL7 in High-Fat Diet-Fed ApoE⁻/⁻ Mice. PLOS One, 21(7), e0354719. https://doi.org/10.1371/journal.pone.0354719
Vancouver
Cheng X, Dai F, Mahmut D, Huang X, Wang Q, Zhang B. Glutamate administration is associated with aggravated atherosclerosis and altered expression of RAPGEF1, OPN, and MYL7 in High-Fat Diet-Fed ApoE⁻/⁻ Mice. PLOS One. 2026;21(7):e0354719. doi:10.1371/journal.pone.0354719
BibTeX
@article{Cheng2026,
author = {Cheng, Xiuli and Dai, Fanshu and Mahmut, Dilraba and Huang, Xingya and Wang, Qin and Zhang, Biao},
title = {Glutamate administration is associated with aggravated atherosclerosis and altered expression of RAPGEF1, OPN, and MYL7 in High-Fat Diet-Fed ApoE⁻/⁻ Mice},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0354719},
doi = {10.1371/journal.pone.0354719}
}
EUVIMED